滤泡性淋巴瘤-话题@MedSci

#滤泡性淋巴瘤#

69篇内容 | 3987人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1278786, encodeId=48db12e87868b, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：MiR-150下调通过上调FOXP1促进滤泡性淋巴瘤向高级别淋巴瘤转化, objectType=article, longId=149072, objectId=da1a1490e2ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da1a1490e2ca, replyNumber=0, likeNumber=115, createdTime=2018-09-20, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da1a1490e2ca, moduleTitle=Blood：MiR-150下调通过上调FOXP1促进滤泡性淋巴瘤向高级别淋巴瘤转化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da1a1490e2ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278785, encodeId=5e0112e8785d2, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=2018 多学科意见书：慢性淋巴细胞白血病和滤泡性淋巴瘤应用艾代拉利司治疗相关不良事件的管理, objectType=article, longId=148933, objectId=8f99148933a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f99148933a1, replyNumber=0, likeNumber=52, createdTime=2018-09-17, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f99148933a1, moduleTitle=2018 多学科意见书：慢性淋巴细胞白血病和滤泡性淋巴瘤应用艾代拉利司治疗相关不良事件的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f99148933a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278784, encodeId=cd6212e8784cc, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=NEJM：来那度胺+利妥昔单抗用于未经治疗的晚期滤泡性淋巴瘤, objectType=article, longId=148651, objectId=82c314865156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c314865156, replyNumber=0, likeNumber=75, createdTime=2018-09-13, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c314865156, moduleTitle=NEJM：来那度胺+利妥昔单抗用于未经治疗的晚期滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c314865156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278783, encodeId=3d8912e8783bf, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：十二指肠型滤泡性淋巴瘤, objectType=article, longId=147150, objectId=2be914e15021, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be914e15021, replyNumber=0, likeNumber=75, createdTime=2018-08-23, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be914e15021, moduleTitle=Blood：十二指肠型滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be914e15021)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278782, encodeId=0a9412e87827f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=J Gastroen Hepatol：无症状且肿瘤负担较低的肠滤泡性淋巴瘤的治疗方法选择, objectType=article, longId=145683, objectId=3a2914568355, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a2914568355, replyNumber=0, likeNumber=61, createdTime=2018-08-03, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a2914568355, moduleTitle=J Gastroen Hepatol：无症状且肿瘤负担较低的肠滤泡性淋巴瘤的治疗方法选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a2914568355)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278781, encodeId=14a412e878111, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet haemat：利妥昔单抗可显著降低滤泡性淋巴瘤向侵袭性淋巴瘤转化的风险, objectType=article, longId=142572, objectId=f2021425e29a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2021425e29a, replyNumber=0, likeNumber=70, createdTime=2018-07-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2021425e29a, moduleTitle=Lancet haemat：利妥昔单抗可显著降低滤泡性淋巴瘤向侵袭性淋巴瘤转化的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2021425e29a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278780, encodeId=9b0312e878032, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet Oncol：基因表达谱数据再建新功：精准判断部分滤泡性淋巴瘤患者的预后, objectType=article, longId=136177, objectId=137b1361e70a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=137b1361e70a, replyNumber=0, likeNumber=44, createdTime=2018-04-24, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=137b1361e70a, moduleTitle=Lancet Oncol：基因表达谱数据再建新功：精准判断部分滤泡性淋巴瘤患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=137b1361e70a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278779, encodeId=a71812e8779c5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Gulf J Oncolog：眼睑淋巴样增生：一例原发性滤泡性淋巴瘤病例, objectType=article, longId=134446, objectId=af94134446d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af94134446d6, replyNumber=0, likeNumber=88, createdTime=2018-04-08, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af94134446d6, moduleTitle=Gulf J Oncolog：眼睑淋巴样增生：一例原发性滤泡性淋巴瘤病例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af94134446d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278778, encodeId=631d12e8778bb, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：结合初始和诱导后PET，建立更为准确的预测滤泡性淋巴瘤患者预后的模型, objectType=article, longId=133082, objectId=210113308256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210113308256, replyNumber=0, likeNumber=65, createdTime=2018-03-23, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210113308256, moduleTitle=Blood：结合初始和诱导后PET，建立更为准确的预测滤泡性淋巴瘤患者预后的模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=210113308256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278777, encodeId=10d012e877710, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet haemat：Voxtalisib（XL765）用于滤泡性淋巴瘤患者可获得良好的治疗效果, objectType=article, longId=132542, objectId=4f8e13254254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f8e13254254, replyNumber=0, likeNumber=83, createdTime=2018-03-17, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f8e13254254, moduleTitle=Lancet haemat：Voxtalisib（XL765）用于滤泡性淋巴瘤患者可获得良好的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f8e13254254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278776, encodeId=973212e8776ba, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=CLIN CANCER RES：滤泡性淋巴瘤中表达TIGIT的T细胞增多, objectType=article, longId=130882, objectId=c3ec130882e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3ec130882e6, replyNumber=0, likeNumber=64, createdTime=2018-03-01, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3ec130882e6, moduleTitle=CLIN CANCER RES：滤泡性淋巴瘤中表达TIGIT的T细胞增多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3ec130882e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278775, encodeId=f2e012e877577, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Br J Haematol：利妥昔单抗诱导治疗无症状滤泡性淋巴瘤省钱又有效？, objectType=article, longId=130821, objectId=fe7113082182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe7113082182, replyNumber=0, likeNumber=42, createdTime=2018-03-01, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe7113082182, moduleTitle=Br J Haematol：利妥昔单抗诱导治疗无症状滤泡性淋巴瘤省钱又有效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe7113082182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278774, encodeId=63ea12e87748f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet haemat：R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性, objectType=article, longId=127695, objectId=d57d12e6952c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d57d12e6952c, replyNumber=0, likeNumber=73, createdTime=2018-01-27, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d57d12e6952c, moduleTitle=Lancet haemat：R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d57d12e6952c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278773, encodeId=ca7c12e8773ff, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。, objectType=article, longId=120773, objectId=59cb120e7346, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59cb120e7346, replyNumber=0, likeNumber=78, createdTime=2017-11-22, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59cb120e7346, moduleTitle=Blood：FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59cb120e7346)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278772, encodeId=5dcc12e877258, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：依鲁替尼治疗复发性或难治性滤泡性淋巴瘤的效果。, objectType=article, longId=118210, objectId=31021182100f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31021182100f, replyNumber=0, likeNumber=66, createdTime=2017-11-01, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31021182100f, moduleTitle=Blood：依鲁替尼治疗复发性或难治性滤泡性淋巴瘤的效果。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31021182100f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278771, encodeId=910812e877108, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=NEJM：Obinutuzumab治疗滤泡性淋巴瘤的效果如何？, objectType=article, longId=115357, objectId=191e11535e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=191e11535e34, replyNumber=0, likeNumber=83, createdTime=2017-10-09, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=191e11535e34, moduleTitle=NEJM：Obinutuzumab治疗滤泡性淋巴瘤的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=191e11535e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278770, encodeId=e20b12e877032, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=治疗复发性滤泡性淋巴瘤的新疗法, objectType=article, longId=113010, objectId=afe9113010c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe9113010c9, replyNumber=0, likeNumber=62, createdTime=2017-09-18, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe9113010c9, moduleTitle=治疗复发性滤泡性淋巴瘤的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afe9113010c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278769, encodeId=7fb312e876961, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=BJH:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？, objectType=article, longId=108312, objectId=cde91083121f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cde91083121f, replyNumber=0, likeNumber=96, createdTime=2017-08-11, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cde91083121f, moduleTitle=BJH:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cde91083121f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278768, encodeId=f11d12e8768c4, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Brit J Haematol:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？, objectType=article, longId=108284, objectId=1f1c10828430, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f1c10828430, replyNumber=0, likeNumber=70, createdTime=2017-08-11, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f1c10828430, moduleTitle=Brit J Haematol:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f1c10828430)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278767, encodeId=19d512e87679f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet Haematol：利妥昔单抗一线治疗滤泡性淋巴瘤：皮下vs静脉, objectType=article, longId=105799, objectId=110d105e99fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=110d105e99fc, replyNumber=0, likeNumber=62, createdTime=2017-07-19, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=110d105e99fc, moduleTitle=Lancet Haematol：利妥昔单抗一线治疗滤泡性淋巴瘤：皮下vs静脉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=110d105e99fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

滤泡性淋巴瘤

2020-05-29

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：MiR-150下调通过上调FOXP1促进滤泡性淋巴瘤向高级别淋巴瘤转化

2018-09-20

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

2018 多学科意见书：慢性淋巴细胞白血病和滤泡性淋巴瘤应用艾代拉利司治疗相关不良事件的管理

2018-09-17

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

NEJM：来那度胺+利妥昔单抗用于未经治疗的晚期滤泡性淋巴瘤

2018-09-13

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：十二指肠型滤泡性淋巴瘤

2018-08-23

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

J Gastroen Hepatol：无症状且肿瘤负担较低的肠滤泡性淋巴瘤的治疗方法选择

2018-08-03

仁者大医 (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet haemat：利妥昔单抗可显著降低滤泡性淋巴瘤向侵袭性淋巴瘤转化的风险

2018-07-07

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet Oncol：基因表达谱数据再建新功：精准判断部分滤泡性淋巴瘤患者的预后

2018-04-24

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Gulf J Oncolog：眼睑淋巴样增生：一例原发性滤泡性淋巴瘤病例

2018-04-08

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：结合初始和诱导后PET，建立更为准确的预测滤泡性淋巴瘤患者预后的模型

2018-03-23

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet haemat：Voxtalisib（XL765）用于滤泡性淋巴瘤患者可获得良好的治疗效果

2018-03-17

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

CLIN CANCER RES：滤泡性淋巴瘤中表达TIGIT的T细胞增多

2018-03-01

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Br J Haematol：利妥昔单抗诱导治疗无症状滤泡性淋巴瘤省钱又有效？

2018-03-01

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet haemat：R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性

2018-01-27

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。

2017-11-22

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：依鲁替尼治疗复发性或难治性滤泡性淋巴瘤的效果。

2017-11-01

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

NEJM：Obinutuzumab治疗滤泡性淋巴瘤的效果如何？

2017-10-09

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

治疗复发性滤泡性淋巴瘤的新疗法

2017-09-18

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

BJH:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？

2017-08-11

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Brit J Haematol:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？

2017-08-11

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet Haematol：利妥昔单抗一线治疗滤泡性淋巴瘤：皮下vs静脉

2017-07-19

科室
- - 订阅+
  - 更多科室
工具
服务